EBIT (Annual)

EBIT: Income before interest and taxes.

Vertex Pharmaceuticals Incorporated (VRTX) had EBIT of $-232.90M for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$11.02B
Net Income	$-535.60M
Cost of Goods Sold	$1.53B
Gross Profit	$9.49B
Operating Expenses	$11.25B
Operating Income	$-232.90M
Non-Operating Income/Expense	$481.40M
Pre-Tax Income	$248.50M
Normalized Pre-Tax Income	$248.50M
Income after Taxes	$-535.60M
Income from Continuous Operations	$-535.60M
Consolidated Net Income/Loss	$-535.60M
Normalized Income after Taxes	$-535.60M
EBIT	$-232.90M
EBITDA	$-25.70M
Weighted-Average Shares Outstanding (Basic)	257.90M
Weighted-Average Shares Outstanding (Diluted)	257.90M
Earnings per Share (EPS) (Basic)	$-2.08
Earnings per Share (EPS) (Diluted)	$-2.08
Balance Sheet Financials
Current Assets	$9.60B
Property, Plant, and Equipment	$1.23B
Long-Term Assets	$12.94B
Total Assets	$22.53B
Current Liabilities	$3.56B
Long-Term Debt	$112.80M
Long-Term Liabilities	$2.56B
Total Liabilities	$6.12B
Common Equity	$16.41B
Tangible Shareholders Equity	$14.50B
Shareholders Equity	$16.41B
Common Shares Outstanding	256.94M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-492.60M
Cash Flow from Investing Activities	$-3.77B
Cash Flow from Financial Activities	$-1.49B
Beginning Cash	$10.37B
End Cash	$4.57B
Increase/Decrease in Cash	$-5.80B
Stock-Based Compensation	$698.50M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.69
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.01
Debt to Equity Ratio	0.01
Gross Margin	86.11%
Operating Margin	-2.11%
EBIT Margin	-2.11%
EBITDA Margin	-0.23%
Pre-Tax Profit Margin	2.25%
Profit Margin	-4.86%
Free Cash Flow	$-790.30M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.49
Inventory Turnover	1.27
Receiveable Turnover	6.85
Days Sales in Receivables	53.31
Return on Equity	-3.26%
Return on Tangible Equity	-3.69%
Return on Assets	-2.38%
Return on Investments	-3.24%
Book Value Per Share	$63.87
Free Cash Flow per Share	$-3.06
Operating Cash Flow per Share	$-1.91

Data from Zacks Investment Research, Inc.